Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (January 2023)
22 slides from Nemaura Medical's investor presentation, Jan 25, 2023
Slide 1: Corporate Presentation 25th January 2023
Corporate Presentation 25 th January 2023 Nasdaq : NMRD
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms su
Slide 3: What is the market space Nemaura is trying to address?
What is the market space Nemaura is trying to address?
Slide 4: Diabetes prevalence and medical expenditure
A recent article in Forbes 1 states: People with diagnosed diabetes incur average medical expenditures of $ 16 , 752 per year , of which about $ 9 , 601 is attributed to diabetes . The CDC estimates that 96 , 000 , 000 adults ( 38 % of the population) in the United States are pre - diabetic and 80 %
Slide 5: Non-invasive daily wear continuous glucose sensor
To address this, we developed a Non - invasive daily wear continuous Glucose sensor targeting: Clinical Market: Type 2 diabetes: >60 million people in Europe 2 Consumer market: Pre - diabetes and Obesity: >90 million people 1 in USA [This market is currently deemed to be the largest opportunity for
Slide 6: Our Goals and What we have delivered so far
Our Goals and What we have delivered so far.. TARGET : Develop sugarBEAT ® a wearable device form factor (see image on left). STATUS : Complete TARGET : Complete Pivotal clinical program and obtain CE approval STATUS : Complete TARGET : Receive first purchase order for sugarBEAT ® STATUS : Complete
Slide 7: Our Goals and What we have delivered so far (continued)
Our Goals and What we have delivered so far.. TARGET: Develop a a Metabolic health and diabetes management program leveraging off sensor platform STATUS: Complete: BEATdiabetes.life & Miboko.com TARGET: Develop launch plans for BEAT®diabetes and Miboko . STATUS: Entered into preliminary agreement wi
Slide 8: Future targets
Future targets.. TARGET: Obtain FDA approval for sugarBEAT ® TARGET: Scale - up manufacture to support sales in UK, Europe & and Middle East through licensees TARGET: Build market share in USA with employers and insurers, for the BEAT®diabetes and Miboko (non - medical) programs. TARGET: Launch suga
Slide 9: sugarBEAT Example of Volunteer data
sugarBEAT ® Example of Volunteer data compared with BGM and Invasive CGM Blue: Finger Prick BGM (Blood glucose meter) Red: Invasive CGM sugarBEAT® Raw data presented (prior to algorithmic conversion, demonstrating tight correlation)
Slide 10: sugarBEAT Example of Volunteer data (Non-diabetic)
sugarBEAT ® Example of Volunteer data (Non - diabetic)
Slide 11: Product Positioning
Product Positioning Medical: sell sugarBEAT ® sensors Diabetes Management (non - medical): BEATdiabetes program and sensors Consumer health and wellbeing: Miboko sensor and app
Slide 12: Product Positioning – Medical
Product Positioning – Medical sugarBEAT® CGM sales through Licensee(s) – no further marketing spend required on Nemaura’s part thus minimizing cost of sales. Support UK Licensee: Licensee engaged in studies designed to support reimbursement from the UK government. Middle East: Provisional order rece
Slide 13: Product Positioning – Type 2 Diabetes
Product Positioning – Type 2 Type 2 Diabetes management and reversal using BEATdiabetes program and sensors • Signed term sheet with Eversana who have a 6000+ salesforce, to sell the program B to B. • Aiming for reimbursement for T2 diabetes management
Slide 14: Product Positioning – Consumer
Product Positioning – Consumer Metabolic health and wellbeing: Miboko app • Phase 1 Beta running • Piloting with NHS in UK • Positive feedback thus far • Aiming for reimbursement for preventative medicine/high risk persons • Targeting partnership/collaborations in 2023
Slide 15: Marketing Strategy – Plug-in
Marketing Strategy – Plug - in Recent feedback suggests there is a significant business case to offer the Metabolic health program (from Miboko ), and the proBEAT sensor and auto - generated progress report as plug - ins to existing diabetes management and metabolic health programs. In the USA alone
Slide 16: Competitive landscape
Competitive landscape Noom: Over 50 million Subscribers, >$400m Revenues in 2020 5 Miboko USP: A holistic Metabolic health approach to weight loss and better health supported using our proprietary wearable sensor that gives an insight in to what’s really happening inside the body
Slide 17: sugarBEAT Regulatory Status
sugarBEAT ® Regulatory Status ▪ CE Approved Class 2b Medical Device in Europe ▪ FDA PMA submitted and in review • FDA Bio - monitoring Division (BIMO) Audit conducted in December 2021 at Nemaura’s UK facility. A single 483 observation was issued. Company submitted a full and complete response to FDA
Slide 18: Future Product Opportunities Leveraging the BEAT Technology
CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival BODY TEMPERATURE MONITORING Gives a more accurate and l
Slide 19: Future Product Opportunities Leveraging the BEAT Technology
ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with individual’s drinking habits. Prevention of progression - to - alcohol - related disease DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan for patients. Global
Slide 20: Intellectual Property
Intellectual Property ▪ IP consists of several Filed Patents and substantial know - how ▪ Some sensor - related patents are not yet published, relating to novel device and composition
Slide 21: Summary
Summary ▪ Revenue generating and ramp - up in revenues anticipated through sales and potential new partnerships ▪ First mover advantage with the non - invasive sensor platform ▪ Simple subscription - based revenue generation models. ▪ Highly Scalable business model with potential for rapid growth an
Slide 22: References
References 1. https://www.forbes.com/sites/stephenbrozak/2022/11/07/diabetesthe - pandemic - is - here - how - do - we - treat - it/?sh=114c799b65be 2. https://www.who.int/europe/health - topics/diabetes#tab=tab_1 3. https://www.cdc.gov/diabetes/library/reports/reportcard/national - dpp.html
Nemaura Medical — Investor Presentation (January 2023) on 6ix